BioSpace News Archive

Firdapse® Launch Momentum Continues with Q3 Net Revenues of $30.9 Million

AbbVie Inc. announced that it has priced its previously announced private offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of $30 billion (collectively, the “Notes”).

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the third quarter and nine months ended September 30, 2019, and provided a corporate update.

Harpoon Therapeutics, Inc. announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences

Calithera Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2019. As of September 30, 2019, cash equivalents and investments totaled $133.6 million.

BeiGene, Ltd. reported recent business highlights, anticipated upcoming milestones, and financial results for the third quarter and first nine months of 2019.

Initiated patient dosing in Phase 1 clinical study of lead program CUE-101 in head and neck squamous cell carcinoma (HNSCC)

Supernus Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that the Company’s management will present a Company overview and update, as well as host investor meetings, at the following November conferences

Organogenesis Holdings Inc. reported financial results for its third quarter ended September 30, 2019.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced its intention to offer and sell 2,000,000 shares of its Class A common stock in an underwritten public offering pursuant to an existing shelf registration statement.